Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 LI-COR to Offer Early-Phase cGMP Materials | Contract Pharma

What are you searching for?

Sign in
Breaking News

LI-COR to Offer Early-Phase cGMP Materials

Expands contract manufacturing services to include synthesis and conjugation services for early-phase cGMP production

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Building on its expertise in reagent and dye production, LI-COR is expanding its services to include synthesis and conjugation services for early-phase cGMP production.

“We offer a variety of custom services and can apply our unique expertise in dye and probe development for intra-operative surgery to help researchers,” said Bambi Reynolds, senior business development manager, LI-COR. “We have expanded our production facility to accommodate contract manufacturing for both pre-clinical and early phase clinical applications.”

LI-COR offers development and manufacturing of dyes and small molecules including custom derivatives of fluorescent dyes and active pharmaceutical ingredient (API) manufacturing at its Lincoln, NE, facility.

“Our clients in need of dye conjugated biomolecules are able to benefit from our extensive experience in biology and chemistry services that we have developed for our instrumentation platforms,” said Ms. Reynolds.

With more than 20 years of bioconjugation experience, LI-COR is a pioneer in the use of near-infrared technology as a detection method. In the early 1990s LI-COR introduced near-infrared (NIR) DNA sequencing technology that has led to other pre-clinical applications including protein and small animal imaging using NIR. This preclinical development has led to two near-infrared dyes being translated into the clinical trials using targeted NIR as a method for both detection and treatment of various types of cancer.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics